{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Teng C"],"funding":["Hainan Provincial Natural Science Foundation of China","the Research Foundation of Hainan University","National Natural Science Foundation of China"],"pagination":["5466"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9785909"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(24)"],"pubmed_abstract":["Small synthetic TLR7/8-agonists can be used as vaccine adjuvants to enhance cell and humoral-mediated immune responses to specific antigens. Despite their potency, after local injection they can be dispersed to undesired body parts causing high reactogenicity, limiting their clinical applications. Here we describe a vaccination strategy that employs the covalent conjugate of a mannose and TLR7/8 agonist as a vaccine adjuvant to take advantage of mannose binding C-type lectins on dendritic cells to enhance the vaccine's immunogenicity. The mannose-TLR7/8 agonist conjugate can self-assemble into nanoparticles with the hydrophilic mannose on the outside and hydrophobic TLR7/8 agonist inside. Although its ability to stimulate HEK-Blue<sup>TM</sup> hTLR7/8 cells dropped, it can efficiently stim"],"journal":["Polymers"],"pubmed_title":["Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer."],"pmcid":["PMC9785909"],"funding_grant_id":["82073697","821MS028","KYQD(ZR)20087","82103988","821CXTD1011"],"pubmed_authors":["Li H","Yang J","Zong C","Meng S","Teng C","Hu Y","Sun T","Mao H","Meng X"],"additional_accession":[]},"is_claimable":false,"name":"Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.","description":"Small synthetic TLR7/8-agonists can be used as vaccine adjuvants to enhance cell and humoral-mediated immune responses to specific antigens. Despite their potency, after local injection they can be dispersed to undesired body parts causing high reactogenicity, limiting their clinical applications. Here we describe a vaccination strategy that employs the covalent conjugate of a mannose and TLR7/8 agonist as a vaccine adjuvant to take advantage of mannose binding C-type lectins on dendritic cells to enhance the vaccine's immunogenicity. The mannose-TLR7/8 agonist conjugate can self-assemble into nanoparticles with the hydrophilic mannose on the outside and hydrophobic TLR7/8 agonist inside. Although its ability to stimulate HEK-Blue<sup>TM</sup> hTLR7/8 cells dropped, it can efficiently stim","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-18T15:59:27.903Z","creation":"2025-04-07T02:55:56.429Z"},"accession":"S-EPMC9785909","cross_references":{"pubmed":["36559833"],"doi":["10.3390/polym14245466"]}}